Free MN MPJE Exam Flashcards

NABP develops and administers the MPJE. The Minnesota Board determines eligibility, licenses and disciplines Minnesota pharmacists and pharmacies, and enforces Minnesota Statutes chapter 151 and Board rules.

The license expires March 1 each year. The renewal application is due on or before February 1; an application received after March 1 carries a late filing fee in addition to the renewal fee.

A pharmacist must complete at least 30 hours of approved continuing education during each two-year period and report participation by September 30 of each even-numbered year, subject to any authorized exemption or extension.

No. Registration must exist before the person performs any pharmacy-technician task; registration itself is not a Board determination that the person is competent.

Registration expires December 31 each year, and the renewal application is due on or before December 1. The technician must report a name, residence, or workplace change within 10 days.

The current minimum age is 18. The rule also contains a narrow grandfather provision for certain people registered before January 1, 2012.

A technician may perform tasks not reserved to a pharmacist or intern only when they do not require professional judgment. A pharmacist, practitioner, or authorized intern must certify technician-prepared products for accuracy before release.

Apply both layers. Rule 6800.3850 starts ordinary work at 2:1 and allows 3:1 for specified IV-admixture, patient-specific unit-dose, prepackaging, and compounding functions. Section 151.102 provides the statutory ceiling, a conditional certified-technician +1, and a Board-petition pathway; 3:1 or 4:1 is not universal.

A licensed pharmacist stationed in the same work area must be able to control the technician's work. Ultimate responsibility for the technician's actions remains with that supervising pharmacist.

Generally no. A pharmacist may be designated PIC of only one pharmacy, subject to a limited Board waiver for a pharmacist serving a hospital pharmacy part time.

The pharmacy must immediately notify the Board, immediately designate a successor, and immediately report that designation. The successor must return the Board's prescribed forms within 10 days after receiving them.

Identify every applicable rule and apply the prevailing law in Minnesota. Where both laws operate, satisfy the more restrictive requirement; first consider whether federal law preempts a conflicting state rule.

An authorized practitioner must issue it within lawful scope and for a legitimate patient-care purpose. A technically complete order is not valid when its issuer lacks authority or it falls outside legitimate professional practice.

Only a pharmacist or a registered intern under immediate and direct pharmacist supervision may retrieve a new verbal prescription. A technician may retrieve only an authorization for unchanged refills of a prescription the pharmacy previously dispensed.

Except for drug orders administered in an acute-care hospital, an electronic prescription may be transmitted only to the pharmacy the patient chooses. Electronic controlled-substance prescriptions must also meet DEA rules.

None. Each additional dispensing requires lawful prescription authority; multiple separate prescriptions with permitted earliest-fill instructions are not refills.

No more than five refills within six months after the issue date. After either ceiling is reached, a new prescription is required; Schedule V is not subject to this federal five-refill ceiling.

Only in an emergency as defined by federal law, and only the quantity needed during the emergency. The prescriber must deliver the required written or electronic follow-up within seven days; otherwise the pharmacist must notify DEA.

The pharmacist shares responsibility for ensuring that the prescription serves a legitimate medical purpose in the usual course of professional practice. Unresolved red flags cannot be ignored merely because a prescriber signed the order.

Overuse or underuse, therapeutic duplication, drug-disease contraindications, drug interactions, incorrect dose or duration, drug-allergy interactions, and clinical abuse or misuse. The pharmacist must take appropriate steps to resolve an identified problem.

At least two years after the last entry. Before dispensing, the pharmacist must examine the profile for harmful interactions and perform the required prospective review.

No. Only a pharmacist or an intern under immediate and direct pharmacist supervision may override an alert, and the PIC must maintain written procedures for handling alerts.

Refusing to consult, evading consultation requirements, or discouraging consultation about a drug's contents, therapeutic value, use, or price is unprofessional conduct.

Generally only with the patient's express oral or written consent or a court order. The rules preserve specific care-related disclosures, including lawful transfers and drug-therapy information to treating health professionals.

Document the refill date, the authorizing practitioner, the practitioner's communicating agent if applicable, any quantity different from the original order, and the unique identifier of the pharmacist who refills it.

They include verifying the order, choosing the drug and supplier, receiving verbal orders, establishing an initial compounded formula, certifying the finished order, and obtaining refill permission when required.

No. Certification includes checking the source container, final label, contents, drug, strength, dosage form, patient profile, and documenting the certifier's unique identifier before release.

The PIC must submit a written response within 30 days describing steps taken or proposed to eliminate the deficiencies. Failure to respond or correct them can support discipline.

A licensed pharmacist or registered intern must communicate directly with a licensed pharmacist or registered intern at the other pharmacy. A label or informal copy alone has informational value, not the legal status of a prescription.

No. Minnesota's rule expressly prohibits Schedule II prescription transfers, so the more permissive federal rule for a one-time transfer of certain electronic controlled-substance prescriptions does not authorize one in Minnesota.

For a new prescription, the pharmacist must personally initiate counseling after reviewing the patient record; a refill requires counseling when professional judgment says it is needed. A patient may decline, and a material variation or omitted consultation and its circumstances must be documented.

Mark it VOID or void all remaining refills electronically, and record the receiving pharmacy, receiving pharmacist or intern, and transfer date. Schedule III-V transfers require the additional controlled-substance identifiers.

Generally no. Narrow exceptions cover hospital inpatient items that never left pharmacy control and qualifying returns from nursing homes or assisted-living facilities that satisfy Rule 6800.2700 storage, nursing-coverage, same-pharmacy, intact-packaging, and product restrictions.

Pharmacy name, address, and phone; patient; prescription number; prescriber; directions; manufacturer or distributor; issue or renewal date; drug name and strength unless the prescriber directs otherwise; needed auxiliary information; and the required physical description for covered dispensed drugs. A central-service identifier is also required when applicable.

The immediate container may carry a partial label with at least the patient name and prescription number, but the complete required label must appear on an appropriate outer container.

No more than one year from packaging or the remaining manufacturer expiration time, whichever is shorter. Professional judgment can require a shorter date.

A qualified pharmacist may initiate, order, and administer FDA-authorized or approved influenza and COVID-19 vaccines to eligible persons age 3 or older, and other FDA-approved vaccines to patients age 6 or older, following current ACIP recommendations and Minnesota training, MIIC review, and reporting duties.

The Poison Prevention Packaging Act generally requires special child-resistant packaging unless the drug or package is exempt or the prescriber or consumer makes a legally permitted nonspecial-packaging request.

No. Rule 6800.3000 says prescriptions faxed by the patient are not to be filled or dispensed; lawful fax transmission must come through an authorized source and meet applicable controlled-substance rules.

Minnesota treats the drug as adulterated when those conditions may have made it injurious to health. It must not be dispensed merely because the container still appears intact.

A pharmacy license expires June 30 each year. The renewal application is due on or before June 1; an application received on or after July 1 carries a late filing fee.

At least one licensed pharmacist must be on duty and physically present whenever the pharmacy is open for business, except for a brief absence arising from pharmacy practice.

Other individuals generally may not access it. The only access is that specifically allowed under the limited institutional-pharmacy provision referenced in Rule 6800.2150.

Minnesota pharmacies compounding nonsterile preparations must follow USP <795>; pharmacies compounding sterile products must follow USP <797>. Other applicable law and standards still apply.

The pharmacy must identify them on a list, and a pharmacist must certify accurate weighing, measuring, or subdivision of each component at each stage before the next stage proceeds.

The pharmacy must notify its patients when central service provides dispensing, DUR, packaging, labeling, delivery, or another pharmacy service.

They must address system operation, downtime, routine backups and maintenance, audit procedures, personnel codes, and responsibilities, while protecting confidentiality and preventing unauthorized record changes.

The comparison must be completed within 72 hours. It ordinarily cannot occur until two hours after initial certification, but a second individual pharmacist may perform it sooner.

Subds. 14-17 provide limited protocol pathways for contraceptives, nicotine replacement, acute-overdose antagonists, and HIV prevention. Effective in 2026, subd. 18 separately allows a qualifying pharmacist to prescribe, administer, and dispense legend drugs and Schedule III-V controlled substances for OUD under training, DEA, documentation, counseling, and nondelegation conditions.

Use packaging and processes that preserve required temperature, use tamper-evident sealing, maintain policies for delayed or compromised shipments and replacement, and provide a mechanism for pharmacist or supervised-intern counseling.